Applovin, Oracle among market cap stock movers on Tuesday

Investing.com -- Jefferies said recent weakness in ANI Pharmaceuticals shares appears driven by investor uncertainty around near term Cortrophin sales guidance and shifting expectations for 2026, rather than a deterioration in the underlying market opportunity.

The brokerage said the stock has pulled back from around $100 after third quarter earnings, citing two likely concerns. The first is whether ANI can hit its fourth quarter Cortrophin revenue guidance of $111 million to $116 million. The second is growing nervousness ahead of management’s 2026 Cortrophin outlook, as investor expectations reset after strong year to date performance.

Jefferies noted that using weekly prescription trends, fourth quarter Cortrophin sales could track closer to $107 million if growth rates mirror last year and net pricing remains flat versus the third quarter.

That estimate excludes potential inventory benefits, which are common in the fourth quarter, and assumes an 85% capture rate. The brokerage said this leaves room for ANI to still land within guidance through inventory movements or modest changes in capture rates.

Using alternative methodologies, including year over year growth assumptions for December and quarter over quarter trends from prior years, Jefferies said fourth quarter Cortrophin revenue could also reach about $114 million, which would place results near the middle of guidance.

Jefferies said the bigger issue is the lack of a clear consensus bar for 2026 Cortrophin revenue. While sell side estimates sit around $445 million, the brokerage said investors have long viewed that figure as stale.

Buy side expectations had moved as high as $525 million following recent script data, but Jefferies said feedback now suggests those numbers are being revised lower, with a wide range of $475 million to $510 million emerging.

The absence of a settled expectation could make the stock’s reaction to 2026 guidance volatile when management updates investors at the January healthcare conference, Jefferies said.

The brokerage described the current setup as driven more by hedge fund trading dynamics than fundamentals, adding that the ACTH market remains healthy, ANI trades at about 8x EBITDA and its long term peak sales estimate for Cortrophin remains above $1 billion.

Investing.com -- Cemtrex Inc (NASDAQ:CETX) stock plunged 19.5% Tuesday after the advanced security technology and industrial services company announced a definitive agreement to sell approximately 800,000 shares at $2.50 per share to a single institutional investor.

The offering, which is expected to generate $2 million in gross proceeds, represents a significant discount to the company’s recent trading price, triggering the sharp selloff. The transaction is expected to close around December 23, 2025, subject to customary closing conditions.

Cemtrex plans to use the net proceeds for general corporate purposes, including working capital and potential acquisitions. The company did not provide specific details about any planned acquisitions or how the capital would be allocated.

The Nasdaq-listed company operates through two main segments: Security and Industrial. The Security segment, led by Vicon Industries, provides advanced video management software and integrated surveillance solutions for enterprise, government, and critical infrastructure clients. Meanwhile, the Industrial segment offers equipment installation and other specialized services to manufacturers through Advanced Industrial Services.

This capital raise comes as Cemtrex seeks to strengthen its financial position, though the steep share price decline indicates investors’ concerns about potential dilution from the new share issuance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Elong Power Holding Ltd (NASDAQ:ELPW) stock plunged 18.5% on Tuesday after the company announced plans to implement a 16-for-1 reverse stock split, a move aimed at maintaining its Nasdaq listing.

The provider of high power battery technologies for commercial and specialty alternative energy vehicles said the split, which was approved by shareholders on November 24, 2025, will take effect on December 26, 2026. Trading will continue under the existing "ELPW" ticker symbol.

The reverse split will reduce Elong Power’s outstanding ordinary shares from approximately 61.3 million to 3.8 million. The company’s Memorandum of Association will be amended to reduce the number of authorized shares and adjust the par value to $0.00016 per share.

Elong Power stated that the reverse split is intended to bring its stock into compliance with Nasdaq’s minimum bid price requirement of $1.00 per share, which is necessary to maintain its listing on the Nasdaq Capital Market.

As part of the restructuring, outstanding warrants and options will be adjusted proportionately in accordance with the reverse split ratio. Shareholders who would otherwise receive fractional shares will have their holdings rounded up to the nearest whole share.

The company filed details of the reverse stock split with the Securities and Exchange Commission on November 3, 2025, as part of its notice of annual general meeting.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Nauticus Robotics Inc (NASDAQ:KITT) stock rose 2.7% on Tuesday after the company announced it had regained compliance with Nasdaq’s continued listing requirements.

The subsea robotics company received formal notice from The Nasdaq Capital Market on December 19, 2025, confirming it had demonstrated compliance with the equity requirement in Rule 5550(b)(1). This development removes an immediate threat of delisting that had been hanging over the company.

According to the notice, Nauticus must maintain compliance with all continued listing requirements through April 14, 2026, or until the end of the Panel’s jurisdiction. Additionally, the company will be subject to a mandatory Panel Monitor through December 19, 2026, in connection with Listing Rule 5815(d)(4)(A).

"We are pleased to be back in Nasdaq compliance. The entire team is now focused on executing the exciting opportunities in the Autonomous Underwater and related Software segments in 2026," said John Gibson, President and CEO of Nauticus Robotics.

Nauticus Robotics develops autonomous subsea robotics and software solutions for various underwater applications. The company’s continued listing on Nasdaq provides it with access to capital markets and potential investors as it pursues growth in the underwater robotics sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Hedge fund giant Citadel plans to return approximately $5 billion in profits from 2025 to investors at the start of next year, according to a CNBC report on Tuesday.

The firm’s flagship Wellington multi-strategy fund achieved a 9.3% gain through last week.

Unlock premium analysis and insights with InvestingPro - get 55% off today

The planned distribution represents only a portion of Citadel’s 2025 profits. The decision to return capital stems from what fund managers perceive as limited investment opportunities heading into 2026. Following this distribution, Citadel will begin 2026 managing $67 billion in assets, down from its current $72 billion.

Profit distributions are not an annual practice for Citadel, but the firm has returned substantial capital to investors over recent years. Including the anticipated 2025 distribution, Citadel will have returned $32 billion in profits to investors since 2017.

Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for the company in blood disorder treatments.

The death occurred on December 14 after the patient experienced serious adverse events, including a cerebellar infarction (stroke) followed by cerebral hemorrhage (brain bleeding), according to a statement from the European Haemophilia Consortium.

The individual, who had hemophilia A with inhibitors, was participating in a long-term open-label extension study of marstacimab (marketed as Hympavzi). The patient had previously participated in the active treatment phase of the parent trial in 2022 and moved into the extension study in 2023.

The fatal event occurred while the patient was receiving marstacimab prophylaxis followed by recombinant factor VIIa, which was administered for perioperative hemostatic management after minor surgery.

Pfizer is working with the study investigator and an independent external Data Monitoring Committee to conduct a comprehensive review of the circumstances surrounding the event. This includes evaluating underlying medical conditions, concurrent medications, and the potential relationship to the study treatment.

The company has notified relevant regulatory authorities and investigators, and surgical management protocols within the marstacimab development program are under review.

Thrombotic events are considered an adverse event for rebalancing therapies such as marstacimab, which works by inhibiting tissue factor pathway inhibitor to enhance thrombin generation. Similar events have been reported with other non-factor hemophilia treatments, particularly in perioperative contexts and when used in combination with clotting factor concentrates or bypassing agents.

Hympavzi was approved last year by regulators in the US and Europe to prevent or reduce the frequency of bleeding episodes in certain patients with hemophilia. The drug was billed as the first of its kind, targeting a protein in the blood clotting process rather than replacing clotting factor.

While the drug has received regulatory approval from the European Medicines Agency for the treatment of hemophilia A or B in patients without inhibitors, its use in patients with inhibitors has not been approved and continues to be evaluated in clinical studies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.